Disease Introduction
Heart valve disease is a condition where the valves either fail to close properly (regurgitation) or fail to open properly (stenosis), leading to abnormal blood flow and increased workload on the heart. The most common causes are aortic stenosis and mitral and tricuspid regurgitation. Typical symptoms include chest tightness, shortness of breath, difficulty breathing after exertion, and lower extremity edema. The general principle of treatment is early detection and assessment, with the cardiac team selecting the appropriate approach from drug therapy, surgical valve replacement or repair, and non-invasive endovascular intervention (such as TAVR).
Cutting-edge high-precision diagnostic and treatment technologies
- Domestic dry valve approved : Jinshi Bio's Prostyle A transcatheter aortic valve system (dry pre-loading, retrievable delivery) was approved for marketing by NMPA in May 2025. Pre-loading is faster and retrievable is safer.
- Regurgitation can also be addressed : The J-Valve TF transfemoral aortic valve system was approved by the NMPA in September 2025. It is specifically designed for patients with severe aortic regurgitation and features an adjustable delivery system that can accommodate complex anatomy such as transverse heart.
- Breakthrough in Tricuspid Valve Intervention : Huihe Medical's transcatheter tricuspid annuloplasty system was approved by the NMPA in March 2025; the domestically produced NeoBlazar tricuspid valve edge-to-edge clip was approved in July 2026, providing a new non-open-chest option for high-risk surgical patients with severe tricuspid regurgitation.
- Expanded indications in guidelines : The 2025 ESC/EACTS guidelines for the management of valvular heart disease suggest that transcatheter aortic valve implantation (TAVI) may be considered for symptomatic severe aortic regurgitation in patients with suitable anatomy who are not suitable for surgery. Specialized devices can reduce the risk of valve displacement and residual regurgitation.
- Dedicated regurgitation devices are available : Starting from November to December 2025, two domestically produced TAVR devices specifically designed for aortic valve regurgitation were approved by the NMPA, marking a shift in China's regurgitation intervention from using stenotic valves to dedicated devices.
